Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4422 | 2013 |
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ... Journal of clinical oncology 26 (8), 1275-1281, 2008 | 3661 | 2008 |
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ... Nature medicine 13 (9), 1050-1059, 2007 | 3377 | 2007 |
DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2347 | 2006 |
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2274 | 2015 |
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 2110 | 2019 |
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ... Nature medicine 15 (10), 1170-1178, 2009 | 2053 | 2009 |
Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1858 | 2016 |
Palbociclib in hormone-receptor–positive advanced breast cancer NC Turner, J Ro, F André, S Loi, S Verma, H Iwata, N Harbeck, S Loibl, ... New England Journal of Medicine 373 (3), 209-219, 2015 | 1713 | 2015 |
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... New England Journal of Medicine 382 (7), 610-621, 2020 | 1623 | 2020 |
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial B Escudier, T Dorval, N Chaput, F André, MP Caby, S Novault, C Flament, ... Journal of translational medicine 3, 1-13, 2005 | 1366 | 2005 |
AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1332 | 2017 |
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1256 | 2017 |
4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1255 | 2018 |
Malignant effusions and immunogenic tumour-derived exosomes F Andre, NEC Schartz, M Movassagh, C Flament, P Pautier, P Morice, ... The Lancet 360 (9329), 295-305, 2002 | 1159 | 2002 |
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative … C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ... Journal of clinical oncology 33 (9), 983-991, 2015 | 1111 | 2015 |
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1086 | 2020 |
Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1080 | 2018 |
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301-1309, 2014 | 1059 | 2014 |
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice … LN Harris, N Ismaila, LM McShane, F Andre, DE Collyar, ... Journal of Clinical Oncology 34 (10), 1134-1150, 2016 | 1002 | 2016 |